The study has provided first evidence on the significant benefits of INEGY, an LDL-cholesterol lowering medication, on kidney patients regardless of the severity of the illness. The research has particularly determined that INEGY can reduce the incidence of major vascular and atherosclerotic events such as non-fatal myocardial infarction or cardiac death, stroke and any revascularization procedure by 16.1%.
The findings of the Sharp study is particularly relevant to the UAE, where one out of every five individuals is living with the condition and more than 50% of those with Type-2 diabetes not even aware of their condition.
The Sharp study, which was supported by Merck, involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Patients included in the trial had lost at least 50% of their normal kidney function, with a third of them requiring dialysis treatment. The study treatment and follow-up continued for an average of five years.
Dr Michael Khouri, Senior Consultant Cardiologist, SKMC AUH, said:
“About 40%-50% of the patients we receive are those suffering from kidney diseases. This is a direct outcome of the high incidence of hypertension and diabetes in the UAE, which predominantly leads to the development of chronic kidney disorders. In our practice, INEGY is generally prescribed as an adjunctive and is about 55%-60% effective in kidney patients.”
Mustafa Nur Elhuda, Professor of Medicine and Consultant Nephrologist, Dubai Healthcare City, said: “It was already known from previous studies that cholesterol-lowering could reduce the risk of heart attacks, strokes and the need for surgery to unblock arteries in people with normal kidney function. In most of these studies, patients with kidney disease were eliminated.
“However, the Sharp trial now shows that cholesterol-lowering has similar effects in people with chronic kidney disease, irrespective of the severity of their illness. Taking INEGY (a combination of ezetimibe and simvastatin) long-term with full compliance will avoid around one quarter of heart attacks, strokes and operations to unblock arteries, leading to their prevention in at least 250,000 people with kidney diseases worldwide each year.”
The use of INEGY is approved by the UAE Ministry of Health and available by prescription in the entire Gulf region.
Sameh Wajih, Medical Advisor, MSD Gulf, said: “The Sharp study conveys good news to patients with end-stage chronic kidney disease. As part of our holistic mission, we look forward to continue supporting and providing study treatments to similar researches that combat the incidence of life-threatening diseases globally.”
The Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) of Oxford University has designed, conducted and analysed Sharp. In addition to Merck, the study received support from Australian National Health and Medical Research Council(NHMRC), the British Heart Foundation (BHF) and the UK Medical Research Council (MRC).
Tuesday, January 18- 2011 @ 15:56 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.